INVO Fertility announced their second quarter 2025 financial results, showcasing growth in revenue and operational highlights.
Notable improvements included revenue increases in clinic operations and advancements in fertility services.
The Company also achieved recognition and received a new patent for their innovative technology.
Revenue Increase
Revenue reached $1,863,654, marking a 1% increase from the previous year and setting a new quarterly record for the Company.
Operational Achievements
INVO Fertility expanded services, launched telehealth capabilities, added PRP therapy, and received a new patent for the INVOcell device.
Strategic Divestiture
Completed divestiture of NAYA Therapeutics to refocus exclusively on fertility operations, aligning with the Company's strategic direction.
- INVO Fertility's financial performance demonstrated growth and stability in clinic revenue and overall operations.
- The recognition on Newsweek's List of America's Best Fertility Clinics reflects the Company's commitment to excellence in fertility care.
- The new patent for the INVOcell device highlights ongoing innovation and intellectual property advancement.
INVO Fertility's focus on operational improvement and innovation in fertility services showcases their commitment to patient-centered care and growth in the market. The strategic divestiture further solidifies the Company's dedication to their core business operations.